Dr. Tsai is an Associate Member in the Department of Hematology at St. Jude Children’s Research Hospital. His research lab focuses on developing genome editing technologies for therapeutics. His group has recently developed CHANGE-seq, a state-of-the-art, sensitive, unbiased, high-throughput method for defining the genome-wide activity of genome editors. Dr. Tsai completed a postdoctoral fellowship at Massachusetts General Hospital & Harvard Medical School, Ph.D. in Functional Genomics and M.S. in Bioinformatics from North Carolina State University. In 2020, he was chosen as one of the American Society for Gene and Cell Therapy Outstanding New Investigators. He is a co-chair of the Steering Committee of the NIH Somatic Cell Genome Editing Consortium.